DCGI has sought post-market surveillance data from the drugmakers of two fixed-dose combination medicines—Imipramine Hydrochloride IP + Diazepam IP tablets used to ease co-morbid anxiety, and Chlorphenamine Maleate IP + Ammonia Chloride IP + Sodium Citrate IP syrup.